$26.43▾ 2.47%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$26.99MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+60.1%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 316% above our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Arcutis Biotherapeutics, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Still growing fast, but the pace has been easing. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$-0.03
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-0.6%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$415.62M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days2 articles
1 bullish1 neutral0 bearish
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate ProfitabilityArcutis Expands Board of Directors with Appointment of Chris Peetz
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.